Sabinsa’s (East Windsor, NJ) Boswellia Cream study results have been released in Clinical Dermatology, suggesting the product is helpful in the treatment of psoriasis.

The cream of Boswellia serrata Roxb extract standardized for 5 percent of 95 percent 3-O-Acetyl-11-Keto Beta Boswellic Acid (AKBBA) was studied in an open label, multi centered phase III clinical trial, evaluating 200 psoriatic patients with application of AKBBA cream three times daily for a period of 12 weeks, reported Sabinsa.

“The evidence shows superior anti-inflammatory responses rates, demonstrating that this non-toxic treatment is beneficial for those suffering from this condition,” reads the report.

Although far from the scope of a dietary supplement, the exploratory process that has gone into such a traditional ingredient showcases Sabinsa’s passion for applying modern day technology to traditional botanicals to help create natural solutions for health, according to the manufacturer.

“Our understanding of this ingredient, originating from one of the earliest compounds released by Sabinsa, called Boswellin®, is growing, and we want the world to know the positive research and the impact it has on human health,” said Dr. Muhammed Majeed, founder of Sabinsa. “Such indications prevalent in ayurvedic texts are now being proven by modern research, in terms of correctly standardizing, isolating the unique compound(s) and ultimately formulating safe and effective products.”

For more information, visit www.sabinsa.com.